Francesco Albano - Concepedia

Author

Francesco Albano

Also Known As

Albano F, Albano, Francesco, Albano,Francesco, F Albano, F. Albano, F., Albano, F.R. Albano, Francesca Albano, Francesco Albano, Ilaria Galeotti

357

Publications

5.5K

Citations

H-Index

Concepts

All Affiliations

University of Bari Aldo Moro Istituti di Ricovero e Cura a Carattere Scientifico University of Bologna Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico St. Eugenio Hospital

About

Francesco Albano is an author at University of Bari Aldo Moro specializing in medicine, hematology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	22	46	1.6K
2	Health Sciences	10	10	328
3	Engineering	4	4	157
4	Natural Sciences	2	2	66
5	Public Health	2	2	112

Francesco Albano

Publications

3.9K

Citations

H-Index

Page 1

	Year	Citations
Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non–High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial Uwe Platzbecker, Giuseppe Avvisati, Laura Cicconi, Journal of Clinical Oncology	2016	375
A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis Francesco Passamonti, Toni Giorgino, Barbara Mora, Leukemia Hematological MalignancyThrombosisTranslational MedicineOncologyMalignant Blood Disorder	2017	323
GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia Adriano Venditti, Alfonso Piciocchi, Anna Candoni, Blood	2019	208
Extramedullary Involvement at Relapse in Acute Promyelocytic Leukemia Patients Treated or Not With All-<i>Trans</i> Retinoic Acid: A Report by the Gruppo Italiano Malattie Ematologiche dell’Adulto Giorgina Specchia, Francesco Lo‐Coco, Marco Vignetti, Journal of Clinical Oncology	2001	134
Differences among young adults, adults and elderly chronic myeloid leukemia patients Fabio Castagnetti, Gabriele Gugliotta, Michele Baccarani, Annals of Oncology Hematological MalignancyFamily MedicineYoung AdultsAgingHealth Policy	2014	97
Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study Simona Soverini, Luana Bavaro, Caterina De Benedittis, Blood	2019	96
The BCR‐ABL1 transcript type influences response and outcome in<scp>P</scp>hiladelphia chromosome‐positive chronic myeloid leukemia patients treated frontline with imatinib Fausto Castagnetti, Gabriele Gugliotta, Massimo Breccia, American Journal of Hematology	2017	91
Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib Fausto Castagnetti, Gabriele Gugliotta, Massimo Breccia, Leukemia Hematological MalignancyMedicineMixed-phenotype Acute LeukemiaHematologyLong-term Outcome	2015	89
Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP Michele Baccarani, Elisabetta Abruzzese, Vincenzo Accurso, Blood Advances Mixed-phenotype Acute LeukemiaPathologyCell Replacement TherapyLogistic AnalysisMyeloid Neoplasia	2019	89
Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP Nicoletta Testoni, Giulia Marzocchi, Simona Luatti, Blood	2009	80

Page 1